v3.26.1
Segment Reporting (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information

The following table presents disaggregated financial information with respect to the Company’s Clinical Stage Biotechnology segment for the three and six months ended June 30, 2026 and 2025, respectively:

 

             
   For the Three Months Ended   For the Six Months Ended 
   June 30,   June 30, 
   2026   2025   2026   2025 
                 
Grant Revenue  $-   $57,480   $-   $336,108 
Operating Expenses:                    
Research and development                    
Conference and conventions   1,413    -    1,413    - 
Clinical trial and research expenses   81,204    733,295    270,341    983,791 
Insurance   40,304    51,827    79,967    99,816 
Payroll and taxes   (14,841)   73,773    63,177    155,952 
Stock-based compensation   13,490    13,490    26,832    26,832 
Rent and utilities   9,297    8,450    18,361    16,596 
Travel and entertainment   263    -    4,373    - 
Total research and development   131,130    880,835    464,464    1,282,987 
General and administrative                    
Depreciation   465    465    932    931 
Directors’ fees   77,500    77,500    155,000    155,000 
Donations   -    -    -    50,000 
Insurance   33,173    26,194    68,477    52,954 
Legal fees   79,446    125,133    222,797    246,155 
Other general and administrative expenses   36,966    32,509    64,597    49,381 
Payroll and taxes   137,144    224,404    358,817    441,117 
Professional fees   139,323    178,303    249,278    336,930 
Rent and utilities   5,381    4,333    10,675    8,984 
Stock-based compensation   292,454    308,580    585,163    610,338 
Travel and entertainment   5,696    -    6,381    - 
Foreign currency transaction gains   -    (48)   -    - 
Total general and administrative   807,548    977,373    1,722,117    1,951,790 
Total Operating Loss   (938,678)   (1,800,728)   (2,186,581)   (2,898,669)
Other Income (Expense):                    
Research and development credit   281    -    281    - 
Interest expense   (50,319)   (51,353)   (103,365)   (115,014)
Net Loss   $(988,716)  $(1,852,081)  $(2,289,665)  $(3,013,683)